Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...
Designing effective lexicons is a critical component of any communications surveillance program, yet even mature teams encounter avoidable pitfalls that diminish accuracy, create operational strain, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results